Crohn's Disease, Active, Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms), Healthy Controls, IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)
Conditions
Brief summary
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
Detailed description
Methods: Sample collection in healthy subjects, IBD and IBS patients: * biopsy of rectum and colon descendens * blood sample collection * collection of sample of nasal mucosa * feces collection * questionnaires * rectal barostat sensitivity measurement * transit measurement of colon * MR scan of brain
Interventions
OTHERSample collection
Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
Sponsors
KU Leuven
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
For group 1: IBS 1. Irritable Bowel Syndrome (IBS) (ROME III criteria) 2. No obvious organic explanation for the IBS symptoms 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms) 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 2. remission is confirmed by at least one sigmoidoscopy 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Only for group 3a: 4. Rome III criteria for IBS Group 4: Healthy controls No abdominal (pain) complaints. Group 5: active Crohn's disease 1\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms) 1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 2. remission is confirmed by at least one sigmoidoscopy 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Exclusion criteria
For all groups: 1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting 2. Abdominal chirurgy (except for an uncomplicated appendectomy)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| differences in visceral sensitivity in different study groups (Visceral sensitivity will me measured by performing a rectal barostat test) | at time of investigation (rectal barostat test), Day 1 | Visceral sensitivity will me measured by performing a rectal barostat test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| immune activity (measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood) | at time of investigation (rectal biopsy), Day 1 | measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood (for example by stimulating Peripheral Blood Mononuclear Cells) |
Countries
Belgium
Contacts
Primary ContactKoen Bellens, MSc
Outcome results
None listed